Invitae Corporation (NYSE: NVTA) Stock Competitors & Peer Comparison
See NVTA's competitors and their performance on the NYSE and across the wider stock market.
Peer Comparison Table: Medical - Diagnostics & Research Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for NVTA and its NYSE peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| NVTA | $0.02 | -35.59% | 5.4M | -0.00 | -$5.36 | N/A |
| DHR-PB | $1,261.26 | -0.78% | 916.8B | 146.01 | $8.64 | +0.69% |
| TMO | $647.89 | +5.67% | 238.4B | 27.70 | $23.16 | +0.29% |
| DHR | $209.36 | +3.01% | 147.1B | 26.23 | $7.98 | +0.69% |
| NTRA | $349.44 | +2.24% | 50.2B | -265.74 | -$1.32 | N/A |
| IQV | $270.94 | +1.98% | 44.4B | 22.22 | $12.13 | N/A |
| A | $153.58 | +4.62% | 42.4B | 25.85 | $5.81 | +0.67% |
| IDXX | $519.83 | +2.02% | 40.3B | 35.92 | $14.22 | N/A |
| ILMN | $228.00 | +9.51% | 33.6B | 44.19 | $5.03 | N/A |
| WAT | $420.59 | +2.58% | 31.2B | 30.49 | $13.68 | N/A |
Stock Comparison
Danaher Corporation (NYSE: DHR-PB)
NVTA vs DHR-PB Comparison September 2026
Invitae Corporation (NYSE: NVTA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVTA stands at 5.4M. In comparison, DHR-PB has a market cap of 916.8B. Regarding current trading prices, NVTA is priced at $0.02 on the NYSE, while DHR-PB trades at $1,261.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVTA currently has a P/E ratio of -0.00, whereas DHR-PB's P/E ratio is 146.01. In terms of profitability, NVTA's ROE is -2.02%, compared to DHR-PB's ROE of +0.08%. Regarding short-term risk, NVTA is more volatile compared to DHR-PB. This indicates higher risk in terms of short-term price fluctuations for NVTA.Check DHR-PB's competition here
Thermo Fisher Scientific Inc. (NYSE: TMO)
NVTA vs TMO Comparison September 2026
Invitae Corporation (NYSE: NVTA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVTA stands at 5.4M. In comparison, TMO has a market cap of 238.4B. Regarding current trading prices, NVTA is priced at $0.02 on the NYSE, while TMO trades at $647.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVTA currently has a P/E ratio of -0.00, whereas TMO's P/E ratio is 27.70. In terms of profitability, NVTA's ROE is -2.02%, compared to TMO's ROE of +0.13%. Regarding short-term risk, NVTA is more volatile compared to TMO. This indicates higher risk in terms of short-term price fluctuations for NVTA.Check TMO's competition here
Danaher Corporation (NYSE: DHR)
NVTA vs DHR Comparison September 2026
Invitae Corporation (NYSE: NVTA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVTA stands at 5.4M. In comparison, DHR has a market cap of 147.1B. Regarding current trading prices, NVTA is priced at $0.02 on the NYSE, while DHR trades at $209.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVTA currently has a P/E ratio of -0.00, whereas DHR's P/E ratio is 26.23. In terms of profitability, NVTA's ROE is -2.02%, compared to DHR's ROE of +0.08%. Regarding short-term risk, NVTA is more volatile compared to DHR. This indicates higher risk in terms of short-term price fluctuations for NVTA.Check DHR's competition here
Natera, Inc. (NASDAQ: NTRA)
NVTA vs NTRA Comparison September 2026
Invitae Corporation (NYSE: NVTA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVTA stands at 5.4M. In comparison, NTRA has a market cap of 50.2B. Regarding current trading prices, NVTA is priced at $0.02 on the NYSE, while NTRA trades at $349.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVTA currently has a P/E ratio of -0.00, whereas NTRA's P/E ratio is -265.74. In terms of profitability, NVTA's ROE is -2.02%, compared to NTRA's ROE of -0.12%. Regarding short-term risk, NVTA is more volatile compared to NTRA. This indicates higher risk in terms of short-term price fluctuations for NVTA.Check NTRA's competition here
IQVIA Holdings Inc. (NYSE: IQV)
NVTA vs IQV Comparison September 2026
Invitae Corporation (NYSE: NVTA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVTA stands at 5.4M. In comparison, IQV has a market cap of 44.4B. Regarding current trading prices, NVTA is priced at $0.02 on the NYSE, while IQV trades at $270.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVTA currently has a P/E ratio of -0.00, whereas IQV's P/E ratio is 22.22. In terms of profitability, NVTA's ROE is -2.02%, compared to IQV's ROE of +0.22%. Regarding short-term risk, NVTA is more volatile compared to IQV. This indicates higher risk in terms of short-term price fluctuations for NVTA.Check IQV's competition here
Agilent Technologies, Inc. (NYSE: A)
NVTA vs A Comparison September 2026
Invitae Corporation (NYSE: NVTA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVTA stands at 5.4M. In comparison, A has a market cap of 42.4B. Regarding current trading prices, NVTA is priced at $0.02 on the NYSE, while A trades at $153.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVTA currently has a P/E ratio of -0.00, whereas A's P/E ratio is 25.85. In terms of profitability, NVTA's ROE is -2.02%, compared to A's ROE of +0.20%. Regarding short-term risk, NVTA is more volatile compared to A. This indicates higher risk in terms of short-term price fluctuations for NVTA.Check A's competition here
IDEXX Laboratories, Inc. (NASDAQ: IDXX)
NVTA vs IDXX Comparison September 2026
Invitae Corporation (NYSE: NVTA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVTA stands at 5.4M. In comparison, IDXX has a market cap of 40.3B. Regarding current trading prices, NVTA is priced at $0.02 on the NYSE, while IDXX trades at $519.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVTA currently has a P/E ratio of -0.00, whereas IDXX's P/E ratio is 35.92. In terms of profitability, NVTA's ROE is -2.02%, compared to IDXX's ROE of +0.72%. Regarding short-term risk, NVTA is more volatile compared to IDXX. This indicates higher risk in terms of short-term price fluctuations for NVTA.Check IDXX's competition here
Illumina, Inc. (NASDAQ: ILMN)
NVTA vs ILMN Comparison September 2026
Invitae Corporation (NYSE: NVTA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVTA stands at 5.4M. In comparison, ILMN has a market cap of 33.6B. Regarding current trading prices, NVTA is priced at $0.02 on the NYSE, while ILMN trades at $228.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVTA currently has a P/E ratio of -0.00, whereas ILMN's P/E ratio is 44.19. In terms of profitability, NVTA's ROE is -2.02%, compared to ILMN's ROE of +0.31%. Regarding short-term risk, NVTA is more volatile compared to ILMN. This indicates higher risk in terms of short-term price fluctuations for NVTA.Check ILMN's competition here
Waters Corporation (NYSE: WAT)
NVTA vs WAT Comparison September 2026
Invitae Corporation (NYSE: NVTA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVTA stands at 5.4M. In comparison, WAT has a market cap of 31.2B. Regarding current trading prices, NVTA is priced at $0.02 on the NYSE, while WAT trades at $420.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVTA currently has a P/E ratio of -0.00, whereas WAT's P/E ratio is 30.49. In terms of profitability, NVTA's ROE is -2.02%, compared to WAT's ROE of +0.02%. Regarding short-term risk, NVTA is more volatile compared to WAT. This indicates higher risk in terms of short-term price fluctuations for NVTA.Check WAT's competition here
Quest Diagnostics Incorporated (NYSE: DGX)
NVTA vs DGX Comparison September 2026
Invitae Corporation (NYSE: NVTA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVTA stands at 5.4M. In comparison, DGX has a market cap of 27.3B. Regarding current trading prices, NVTA is priced at $0.02 on the NYSE, while DGX trades at $246.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVTA currently has a P/E ratio of -0.00, whereas DGX's P/E ratio is 24.39. In terms of profitability, NVTA's ROE is -2.02%, compared to DGX's ROE of +0.14%. Regarding short-term risk, NVTA is more volatile compared to DGX. This indicates higher risk in terms of short-term price fluctuations for NVTA.Check DGX's competition here
Mettler-Toledo International Inc. (NYSE: MTD)
NVTA vs MTD Comparison September 2026
Invitae Corporation (NYSE: NVTA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVTA stands at 5.4M. In comparison, MTD has a market cap of 26.9B. Regarding current trading prices, NVTA is priced at $0.02 on the NYSE, while MTD trades at $1,376.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVTA currently has a P/E ratio of -0.00, whereas MTD's P/E ratio is 30.58. In terms of profitability, NVTA's ROE is -2.02%, compared to MTD's ROE of -12.00%. Regarding short-term risk, NVTA is more volatile compared to MTD. This indicates higher risk in terms of short-term price fluctuations for NVTA.Check MTD's competition here
Labcorp Holdings Inc. (NYSE: LH)
NVTA vs LH Comparison September 2026
Invitae Corporation (NYSE: NVTA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVTA stands at 5.4M. In comparison, LH has a market cap of 25.9B. Regarding current trading prices, NVTA is priced at $0.02 on the NYSE, while LH trades at $324.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVTA currently has a P/E ratio of -0.00, whereas LH's P/E ratio is 18.72. In terms of profitability, NVTA's ROE is -2.02%, compared to LH's ROE of +0.12%. Regarding short-term risk, NVTA is more volatile compared to LH. This indicates higher risk in terms of short-term price fluctuations for NVTA.Check LH's competition here
Guardant Health, Inc. (NASDAQ: GH)
NVTA vs GH Comparison September 2026
Invitae Corporation (NYSE: NVTA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVTA stands at 5.4M. In comparison, GH has a market cap of 23.6B. Regarding current trading prices, NVTA is priced at $0.02 on the NYSE, while GH trades at $176.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVTA currently has a P/E ratio of -0.00, whereas GH's P/E ratio is -50.33. In terms of profitability, NVTA's ROE is -2.02%, compared to GH's ROE of +2.11%. Regarding short-term risk, NVTA is more volatile compared to GH. This indicates higher risk in terms of short-term price fluctuations for NVTA.Check GH's competition here
Exact Sciences Corporation (NASDAQ: EXAS)
NVTA vs EXAS Comparison September 2026
Invitae Corporation (NYSE: NVTA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVTA stands at 5.4M. In comparison, EXAS has a market cap of 20B. Regarding current trading prices, NVTA is priced at $0.02 on the NYSE, while EXAS trades at $104.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVTA currently has a P/E ratio of -0.00, whereas EXAS's P/E ratio is -95.37. In terms of profitability, NVTA's ROE is -2.02%, compared to EXAS's ROE of -0.09%. Regarding short-term risk, NVTA is more volatile compared to EXAS. This indicates higher risk in terms of short-term price fluctuations for NVTA.Check EXAS's competition here
Medpace Holdings, Inc. (NASDAQ: MEDP)
NVTA vs MEDP Comparison September 2026
Invitae Corporation (NYSE: NVTA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVTA stands at 5.4M. In comparison, MEDP has a market cap of 17.3B. Regarding current trading prices, NVTA is priced at $0.02 on the NYSE, while MEDP trades at $618.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVTA currently has a P/E ratio of -0.00, whereas MEDP's P/E ratio is 36.37. In terms of profitability, NVTA's ROE is -2.02%, compared to MEDP's ROE of +1.10%. Regarding short-term risk, NVTA is more volatile compared to MEDP. This indicates higher risk in terms of short-term price fluctuations for NVTA.Check MEDP's competition here
Illumina, Inc. Common Stock Ex-distribution When-Issued (NASDAQ: ILMNV)
NVTA vs ILMNV Comparison September 2026
Invitae Corporation (NYSE: NVTA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVTA stands at 5.4M. In comparison, ILMNV has a market cap of 17B. Regarding current trading prices, NVTA is priced at $0.02 on the NYSE, while ILMNV trades at $107.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVTA currently has a P/E ratio of -0.00, whereas ILMNV's P/E ratio is N/A. In terms of profitability, NVTA's ROE is -2.02%, compared to ILMNV's ROE of N/A. Regarding short-term risk, NVTA is more volatile compared to ILMNV. This indicates higher risk in terms of short-term price fluctuations for NVTA.Check ILMNV's competition here
Revvity, Inc. (NYSE: RVTY)
NVTA vs RVTY Comparison September 2026
Invitae Corporation (NYSE: NVTA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVTA stands at 5.4M. In comparison, RVTY has a market cap of 15.6B. Regarding current trading prices, NVTA is priced at $0.02 on the NYSE, while RVTY trades at $145.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVTA currently has a P/E ratio of -0.00, whereas RVTY's P/E ratio is 26.19. In terms of profitability, NVTA's ROE is -2.02%, compared to RVTY's ROE of +0.03%. Regarding short-term risk, NVTA is more volatile compared to RVTY. This indicates higher risk in terms of short-term price fluctuations for NVTA.Check RVTY's competition here
PerkinElmer, Inc. (NYSE: PKI)
NVTA vs PKI Comparison September 2026
Invitae Corporation (NYSE: NVTA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVTA stands at 5.4M. In comparison, PKI has a market cap of 14.5B. Regarding current trading prices, NVTA is priced at $0.02 on the NYSE, while PKI trades at $115.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVTA currently has a P/E ratio of -0.00, whereas PKI's P/E ratio is 41.45. In terms of profitability, NVTA's ROE is -2.02%, compared to PKI's ROE of +0.03%. Regarding short-term risk, NVTA is more volatile compared to PKI. This indicates higher risk in terms of short-term price fluctuations for NVTA.Check PKI's competition here
ICON Public Limited Company (NASDAQ: ICLR)
NVTA vs ICLR Comparison September 2026
Invitae Corporation (NYSE: NVTA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVTA stands at 5.4M. In comparison, ICLR has a market cap of 13.2B. Regarding current trading prices, NVTA is priced at $0.02 on the NYSE, while ICLR trades at $174.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVTA currently has a P/E ratio of -0.00, whereas ICLR's P/E ratio is 14.07. In terms of profitability, NVTA's ROE is -2.02%, compared to ICLR's ROE of +0.04%. Regarding short-term risk, NVTA is more volatile compared to ICLR. This indicates higher risk in terms of short-term price fluctuations for NVTA.Check ICLR's competition here
Charles River Laboratories International, Inc. (NYSE: CRL)
NVTA vs CRL Comparison September 2026
Invitae Corporation (NYSE: NVTA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVTA stands at 5.4M. In comparison, CRL has a market cap of 13.1B. Regarding current trading prices, NVTA is priced at $0.02 on the NYSE, while CRL trades at $279.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVTA currently has a P/E ratio of -0.00, whereas CRL's P/E ratio is 27.53. In terms of profitability, NVTA's ROE is -2.02%, compared to CRL's ROE of -0.08%. Regarding short-term risk, NVTA is more volatile compared to CRL. This indicates higher risk in terms of short-term price fluctuations for NVTA.Check CRL's competition here
Qiagen N.V. (NYSE: QGEN)
NVTA vs QGEN Comparison September 2026
Invitae Corporation (NYSE: NVTA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVTA stands at 5.4M. In comparison, QGEN has a market cap of 8.8B. Regarding current trading prices, NVTA is priced at $0.02 on the NYSE, while QGEN trades at $43.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVTA currently has a P/E ratio of -0.00, whereas QGEN's P/E ratio is 17.55. In terms of profitability, NVTA's ROE is -2.02%, compared to QGEN's ROE of +0.12%. Regarding short-term risk, NVTA is more volatile compared to QGEN. This indicates higher risk in terms of short-term price fluctuations for NVTA.Check QGEN's competition here
RadNet, Inc. (NASDAQ: RDNT)
NVTA vs RDNT Comparison September 2026
Invitae Corporation (NYSE: NVTA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVTA stands at 5.4M. In comparison, RDNT has a market cap of 6.1B. Regarding current trading prices, NVTA is priced at $0.02 on the NYSE, while RDNT trades at $77.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVTA currently has a P/E ratio of -0.00, whereas RDNT's P/E ratio is 167.65. In terms of profitability, NVTA's ROE is -2.02%, compared to RDNT's ROE of -0.02%. Regarding short-term risk, NVTA is more volatile compared to RDNT. This indicates higher risk in terms of short-term price fluctuations for NVTA.Check RDNT's competition here
Sotera Health Company (NASDAQ: SHC)
NVTA vs SHC Comparison September 2026
Invitae Corporation (NYSE: NVTA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVTA stands at 5.4M. In comparison, SHC has a market cap of 5.4B. Regarding current trading prices, NVTA is priced at $0.02 on the NYSE, while SHC trades at $19.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVTA currently has a P/E ratio of -0.00, whereas SHC's P/E ratio is 19.77. In terms of profitability, NVTA's ROE is -2.02%, compared to SHC's ROE of +0.27%. Regarding short-term risk, NVTA is more volatile compared to SHC. This indicates higher risk in terms of short-term price fluctuations for NVTA.Check SHC's competition here
BillionToOne, Inc. (NASDAQ: BLLN)
NVTA vs BLLN Comparison September 2026
Invitae Corporation (NYSE: NVTA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVTA stands at 5.4M. In comparison, BLLN has a market cap of 4.8B. Regarding current trading prices, NVTA is priced at $0.02 on the NYSE, while BLLN trades at $105.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVTA currently has a P/E ratio of -0.00, whereas BLLN's P/E ratio is 148.96. In terms of profitability, NVTA's ROE is -2.02%, compared to BLLN's ROE of +0.08%. Regarding short-term risk, NVTA is more volatile compared to BLLN. This indicates higher risk in terms of short-term price fluctuations for NVTA.Check BLLN's competition here
Syneos Health, Inc. (NASDAQ: SYNH)
NVTA vs SYNH Comparison September 2026
Invitae Corporation (NYSE: NVTA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVTA stands at 5.4M. In comparison, SYNH has a market cap of 4.5B. Regarding current trading prices, NVTA is priced at $0.02 on the NYSE, while SYNH trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVTA currently has a P/E ratio of -0.00, whereas SYNH's P/E ratio is 61.40. In terms of profitability, NVTA's ROE is -2.02%, compared to SYNH's ROE of +0.08%. Regarding short-term risk, NVTA is more volatile compared to SYNH. This indicates higher risk in terms of short-term price fluctuations for NVTA.Check SYNH's competition here
GRAIL Inc. (NASDAQ: GRAL)
NVTA vs GRAL Comparison September 2026
Invitae Corporation (NYSE: NVTA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVTA stands at 5.4M. In comparison, GRAL has a market cap of 3.3B. Regarding current trading prices, NVTA is priced at $0.02 on the NYSE, while GRAL trades at $76.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVTA currently has a P/E ratio of -0.00, whereas GRAL's P/E ratio is -7.78. In terms of profitability, NVTA's ROE is -2.02%, compared to GRAL's ROE of -0.16%. Regarding short-term risk, NVTA is more volatile compared to GRAL. This indicates higher risk in terms of short-term price fluctuations for NVTA.Check GRAL's competition here
Olink Holding AB (publ) (NASDAQ: OLK)
NVTA vs OLK Comparison September 2026
Invitae Corporation (NYSE: NVTA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVTA stands at 5.4M. In comparison, OLK has a market cap of 3.2B. Regarding current trading prices, NVTA is priced at $0.02 on the NYSE, while OLK trades at $26.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVTA currently has a P/E ratio of -0.00, whereas OLK's P/E ratio is -96.59. In terms of profitability, NVTA's ROE is -2.02%, compared to OLK's ROE of -0.07%. Regarding short-term risk, NVTA is more volatile compared to OLK. This indicates higher risk in terms of short-term price fluctuations for NVTA.Check OLK's competition here
Veracyte, Inc. (NASDAQ: VCYT)
NVTA vs VCYT Comparison September 2026
Invitae Corporation (NYSE: NVTA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVTA stands at 5.4M. In comparison, VCYT has a market cap of 3.2B. Regarding current trading prices, NVTA is priced at $0.02 on the NYSE, while VCYT trades at $40.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVTA currently has a P/E ratio of -0.00, whereas VCYT's P/E ratio is 20.07. In terms of profitability, NVTA's ROE is -2.02%, compared to VCYT's ROE of +0.09%. Regarding short-term risk, NVTA is more volatile compared to VCYT. This indicates higher risk in terms of short-term price fluctuations for NVTA.Check VCYT's competition here
GeneDx Holdings Corp. (NASDAQ: WGS)
NVTA vs WGS Comparison September 2026
Invitae Corporation (NYSE: NVTA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVTA stands at 5.4M. In comparison, WGS has a market cap of 2.8B. Regarding current trading prices, NVTA is priced at $0.02 on the NYSE, while WGS trades at $98.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVTA currently has a P/E ratio of -0.00, whereas WGS's P/E ratio is 262.89. In terms of profitability, NVTA's ROE is -2.02%, compared to WGS's ROE of -0.39%. Regarding short-term risk, NVTA is more volatile compared to WGS. This indicates higher risk in terms of short-term price fluctuations for NVTA.Check WGS's competition here
CareDx, Inc (NASDAQ: CDNA)
NVTA vs CDNA Comparison September 2026
Invitae Corporation (NYSE: NVTA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVTA stands at 5.4M. In comparison, CDNA has a market cap of 2.7B. Regarding current trading prices, NVTA is priced at $0.02 on the NYSE, while CDNA trades at $54.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVTA currently has a P/E ratio of -0.00, whereas CDNA's P/E ratio is 62.67. In terms of profitability, NVTA's ROE is -2.02%, compared to CDNA's ROE of +0.33%. Regarding short-term risk, NVTA is more volatile compared to CDNA. This indicates higher risk in terms of short-term price fluctuations for NVTA.Check CDNA's competition here
Personalis, Inc. (NASDAQ: PSNL)
NVTA vs PSNL Comparison September 2026
Invitae Corporation (NYSE: NVTA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVTA stands at 5.4M. In comparison, PSNL has a market cap of 1.7B. Regarding current trading prices, NVTA is priced at $0.02 on the NYSE, while PSNL trades at $16.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVTA currently has a P/E ratio of -0.00, whereas PSNL's P/E ratio is -14.77. In terms of profitability, NVTA's ROE is -2.02%, compared to PSNL's ROE of -0.46%. Regarding short-term risk, NVTA is more volatile compared to PSNL. This indicates higher risk in terms of short-term price fluctuations for NVTA.Check PSNL's competition here
OPKO Health, Inc. (NASDAQ: OPK)
NVTA vs OPK Comparison September 2026
Invitae Corporation (NYSE: NVTA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVTA stands at 5.4M. In comparison, OPK has a market cap of 1.2B. Regarding current trading prices, NVTA is priced at $0.02 on the NYSE, while OPK trades at $1.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVTA currently has a P/E ratio of -0.00, whereas OPK's P/E ratio is -5.81. In terms of profitability, NVTA's ROE is -2.02%, compared to OPK's ROE of -0.06%. Regarding short-term risk, NVTA is more volatile compared to OPK. This indicates higher risk in terms of short-term price fluctuations for NVTA.Check OPK's competition here
Castle Biosciences, Inc. (NASDAQ: CSTL)
NVTA vs CSTL Comparison September 2026
Invitae Corporation (NYSE: NVTA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVTA stands at 5.4M. In comparison, CSTL has a market cap of 1.1B. Regarding current trading prices, NVTA is priced at $0.02 on the NYSE, while CSTL trades at $35.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVTA currently has a P/E ratio of -0.00, whereas CSTL's P/E ratio is -53.79. In terms of profitability, NVTA's ROE is -2.02%, compared to CSTL's ROE of -0.04%. Regarding short-term risk, NVTA is more volatile compared to CSTL. This indicates higher risk in terms of short-term price fluctuations for NVTA.Check CSTL's competition here
Fulgent Genetics, Inc. (NASDAQ: FLGT)
NVTA vs FLGT Comparison September 2026
Invitae Corporation (NYSE: NVTA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVTA stands at 5.4M. In comparison, FLGT has a market cap of 604.4M. Regarding current trading prices, NVTA is priced at $0.02 on the NYSE, while FLGT trades at $21.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVTA currently has a P/E ratio of -0.00, whereas FLGT's P/E ratio is 2128.00. In terms of profitability, NVTA's ROE is -2.02%, compared to FLGT's ROE of -0.08%. Regarding short-term risk, NVTA is more volatile compared to FLGT. This indicates higher risk in terms of short-term price fluctuations for NVTA.Check FLGT's competition here
GRAIL, Inc. Common Stock (NASDAQ: GRALV)
NVTA vs GRALV Comparison September 2026
Invitae Corporation (NYSE: NVTA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVTA stands at 5.4M. In comparison, GRALV has a market cap of 579.4M. Regarding current trading prices, NVTA is priced at $0.02 on the NYSE, while GRALV trades at $18.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVTA currently has a P/E ratio of -0.00, whereas GRALV's P/E ratio is N/A. In terms of profitability, NVTA's ROE is -2.02%, compared to GRALV's ROE of N/A. Regarding short-term risk, NVTA is more volatile compared to GRALV. This indicates higher risk in terms of short-term price fluctuations for NVTA.Check GRALV's competition here
NeoGenomics, Inc. (NASDAQ: NEO)
NVTA vs NEO Comparison September 2026
Invitae Corporation (NYSE: NVTA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVTA stands at 5.4M. In comparison, NEO has a market cap of 485.4M. Regarding current trading prices, NVTA is priced at $0.02 on the NYSE, while NEO trades at $19.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVTA currently has a P/E ratio of -0.00, whereas NEO's P/E ratio is 145.31. In terms of profitability, NVTA's ROE is -2.02%, compared to NEO's ROE of -0.06%. Regarding short-term risk, NVTA is more volatile compared to NEO. This indicates higher risk in terms of short-term price fluctuations for NVTA.Check NEO's competition here
Global Cord Blood Corporation (NYSE: CO)
NVTA vs CO Comparison September 2026
Invitae Corporation (NYSE: NVTA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVTA stands at 5.4M. In comparison, CO has a market cap of 400.1M. Regarding current trading prices, NVTA is priced at $0.02 on the NYSE, while CO trades at $2.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVTA currently has a P/E ratio of -0.00, whereas CO's P/E ratio is 5.06. In terms of profitability, NVTA's ROE is -2.02%, compared to CO's ROE of +0.11%. Regarding short-term risk, NVTA is more volatile compared to CO. This indicates higher risk in terms of short-term price fluctuations for NVTA.Check CO's competition here
Myriad Genetics, Inc. (NASDAQ: MYGN)
NVTA vs MYGN Comparison September 2026
Invitae Corporation (NYSE: NVTA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVTA stands at 5.4M. In comparison, MYGN has a market cap of 366.5M. Regarding current trading prices, NVTA is priced at $0.02 on the NYSE, while MYGN trades at $4.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVTA currently has a P/E ratio of -0.00, whereas MYGN's P/E ratio is -29.85. In terms of profitability, NVTA's ROE is -2.02%, compared to MYGN's ROE of -0.33%. Regarding short-term risk, NVTA is more volatile compared to MYGN. This indicates higher risk in terms of short-term price fluctuations for NVTA.Check MYGN's competition here
Standard BioTools Inc. (NASDAQ: FLDM)
NVTA vs FLDM Comparison September 2026
Invitae Corporation (NYSE: NVTA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVTA stands at 5.4M. In comparison, FLDM has a market cap of 294.2M. Regarding current trading prices, NVTA is priced at $0.02 on the NYSE, while FLDM trades at $3.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVTA currently has a P/E ratio of -0.00, whereas FLDM's P/E ratio is -4.74. In terms of profitability, NVTA's ROE is -2.02%, compared to FLDM's ROE of +0.18%. Regarding short-term risk, NVTA is more volatile compared to FLDM. This indicates higher risk in terms of short-term price fluctuations for NVTA.Check FLDM's competition here
Prenetics Global Limited (NASDAQ: PRENW)
NVTA vs PRENW Comparison September 2026
Invitae Corporation (NYSE: NVTA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVTA stands at 5.4M. In comparison, PRENW has a market cap of 277.8M. Regarding current trading prices, NVTA is priced at $0.02 on the NYSE, while PRENW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVTA currently has a P/E ratio of -0.00, whereas PRENW's P/E ratio is N/A. In terms of profitability, NVTA's ROE is -2.02%, compared to PRENW's ROE of -0.49%. Regarding short-term risk, NVTA is more volatile compared to PRENW. This indicates higher risk in terms of short-term price fluctuations for NVTA.Check PRENW's competition here
Biodesix, Inc. (NASDAQ: BDSX)
NVTA vs BDSX Comparison September 2026
Invitae Corporation (NYSE: NVTA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVTA stands at 5.4M. In comparison, BDSX has a market cap of 225.5M. Regarding current trading prices, NVTA is priced at $0.02 on the NYSE, while BDSX trades at $28.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVTA currently has a P/E ratio of -0.00, whereas BDSX's P/E ratio is -8.74. In terms of profitability, NVTA's ROE is -2.02%, compared to BDSX's ROE of -7.88%. Regarding short-term risk, NVTA is more volatile compared to BDSX. This indicates higher risk in terms of short-term price fluctuations for NVTA.Check BDSX's competition here
Exagen Inc. (NASDAQ: XGN)
NVTA vs XGN Comparison September 2026
Invitae Corporation (NYSE: NVTA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVTA stands at 5.4M. In comparison, XGN has a market cap of 181M. Regarding current trading prices, NVTA is priced at $0.02 on the NYSE, while XGN trades at $7.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVTA currently has a P/E ratio of -0.00, whereas XGN's P/E ratio is -9.25. In terms of profitability, NVTA's ROE is -2.02%, compared to XGN's ROE of -1.22%. Regarding short-term risk, NVTA is more volatile compared to XGN. This indicates higher risk in terms of short-term price fluctuations for NVTA.Check XGN's competition here
Insight Molecular Diagnostics Inc. (NASDAQ: IMDX)
NVTA vs IMDX Comparison September 2026
Invitae Corporation (NYSE: NVTA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVTA stands at 5.4M. In comparison, IMDX has a market cap of 129.8M. Regarding current trading prices, NVTA is priced at $0.02 on the NYSE, while IMDX trades at $3.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVTA currently has a P/E ratio of -0.00, whereas IMDX's P/E ratio is -2.70. In terms of profitability, NVTA's ROE is -2.02%, compared to IMDX's ROE of +2.72%. Regarding short-term risk, NVTA is more volatile compared to IMDX. This indicates higher risk in terms of short-term price fluctuations for NVTA.Check IMDX's competition here
Genetron Holdings Limited (NASDAQ: GTH)
NVTA vs GTH Comparison September 2026
Invitae Corporation (NYSE: NVTA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVTA stands at 5.4M. In comparison, GTH has a market cap of 127.3M. Regarding current trading prices, NVTA is priced at $0.02 on the NYSE, while GTH trades at $4.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVTA currently has a P/E ratio of -0.00, whereas GTH's P/E ratio is -1.11. In terms of profitability, NVTA's ROE is -2.02%, compared to GTH's ROE of -1.01%. Regarding short-term risk, NVTA is more volatile compared to GTH. This indicates higher risk in terms of short-term price fluctuations for NVTA.Check GTH's competition here
Genetic Technologies Limited (NASDAQ: GENE)
NVTA vs GENE Comparison September 2026
Invitae Corporation (NYSE: NVTA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVTA stands at 5.4M. In comparison, GENE has a market cap of 111.2M. Regarding current trading prices, NVTA is priced at $0.02 on the NYSE, while GENE trades at $0.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVTA currently has a P/E ratio of -0.00, whereas GENE's P/E ratio is -38.25. In terms of profitability, NVTA's ROE is -2.02%, compared to GENE's ROE of -1.85%. Regarding short-term risk, NVTA is more volatile compared to GENE. This indicates higher risk in terms of short-term price fluctuations for NVTA.Check GENE's competition here
Sera Prognostics, Inc. (NASDAQ: SERA)
NVTA vs SERA Comparison September 2026
Invitae Corporation (NYSE: NVTA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVTA stands at 5.4M. In comparison, SERA has a market cap of 76M. Regarding current trading prices, NVTA is priced at $0.02 on the NYSE, while SERA trades at $2.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVTA currently has a P/E ratio of -0.00, whereas SERA's P/E ratio is -3.06. In terms of profitability, NVTA's ROE is -2.02%, compared to SERA's ROE of -0.47%. Regarding short-term risk, NVTA is more volatile compared to SERA. This indicates higher risk in terms of short-term price fluctuations for NVTA.Check SERA's competition here
Precipio, Inc. (NASDAQ: PRPO)
NVTA vs PRPO Comparison September 2026
Invitae Corporation (NYSE: NVTA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVTA stands at 5.4M. In comparison, PRPO has a market cap of 48.6M. Regarding current trading prices, NVTA is priced at $0.02 on the NYSE, while PRPO trades at $25.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVTA currently has a P/E ratio of -0.00, whereas PRPO's P/E ratio is -104.77. In terms of profitability, NVTA's ROE is -2.02%, compared to PRPO's ROE of -0.08%. Regarding short-term risk, NVTA is more volatile compared to PRPO. This indicates higher risk in terms of short-term price fluctuations for NVTA.Check PRPO's competition here
MDxHealth S.A. (NASDAQ: MDXH)
NVTA vs MDXH Comparison September 2026
Invitae Corporation (NYSE: NVTA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVTA stands at 5.4M. In comparison, MDXH has a market cap of 34.6M. Regarding current trading prices, NVTA is priced at $0.02 on the NYSE, while MDXH trades at $0.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVTA currently has a P/E ratio of -0.00, whereas MDXH's P/E ratio is -1.77. In terms of profitability, NVTA's ROE is -2.02%, compared to MDXH's ROE of +1.43%. Regarding short-term risk, NVTA is more volatile compared to MDXH. This indicates higher risk in terms of short-term price fluctuations for NVTA.Check MDXH's competition here
Quantum Cyber N.V. (NASDAQ: QUCY)
NVTA vs QUCY Comparison September 2026
Invitae Corporation (NYSE: NVTA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVTA stands at 5.4M. In comparison, QUCY has a market cap of 30.5M. Regarding current trading prices, NVTA is priced at $0.02 on the NYSE, while QUCY trades at $1.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVTA currently has a P/E ratio of -0.00, whereas QUCY's P/E ratio is -0.06. In terms of profitability, NVTA's ROE is -2.02%, compared to QUCY's ROE of -3.65%. Regarding short-term risk, NVTA is more volatile compared to QUCY. This indicates higher risk in terms of short-term price fluctuations for NVTA.Check QUCY's competition here
Akumin Inc. (NASDAQ: AKU)
NVTA vs AKU Comparison September 2026
Invitae Corporation (NYSE: NVTA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVTA stands at 5.4M. In comparison, AKU has a market cap of 26.3M. Regarding current trading prices, NVTA is priced at $0.02 on the NYSE, while AKU trades at $0.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVTA currently has a P/E ratio of -0.00, whereas AKU's P/E ratio is -0.13. In terms of profitability, NVTA's ROE is -2.02%, compared to AKU's ROE of -5.32%. Regarding short-term risk, NVTA is more volatile compared to AKU. This indicates higher risk in terms of short-term price fluctuations for NVTA.Check AKU's competition here
Chembio Diagnostics, Inc. (NASDAQ: CEMI)
NVTA vs CEMI Comparison September 2026
Invitae Corporation (NYSE: NVTA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVTA stands at 5.4M. In comparison, CEMI has a market cap of 16.7M. Regarding current trading prices, NVTA is priced at $0.02 on the NYSE, while CEMI trades at $0.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVTA currently has a P/E ratio of -0.00, whereas CEMI's P/E ratio is -0.63. In terms of profitability, NVTA's ROE is -2.02%, compared to CEMI's ROE of -0.89%. Regarding short-term risk, NVTA is more volatile compared to CEMI. This indicates higher risk in terms of short-term price fluctuations for NVTA.Check CEMI's competition here
Enzo Biochem, Inc. (NYSE: ENZ)
NVTA vs ENZ Comparison September 2026
Invitae Corporation (NYSE: NVTA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVTA stands at 5.4M. In comparison, ENZ has a market cap of 16.4M. Regarding current trading prices, NVTA is priced at $0.02 on the NYSE, while ENZ trades at $0.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVTA currently has a P/E ratio of -0.00, whereas ENZ's P/E ratio is -2.24. In terms of profitability, NVTA's ROE is -2.02%, compared to ENZ's ROE of -0.39%. Regarding short-term risk, NVTA is more volatile compared to ENZ. This indicates higher risk in terms of short-term price fluctuations for NVTA.Check ENZ's competition here
Psychemedics Corporation (NASDAQ: PMD)
NVTA vs PMD Comparison September 2026
Invitae Corporation (NYSE: NVTA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVTA stands at 5.4M. In comparison, PMD has a market cap of 15.6M. Regarding current trading prices, NVTA is priced at $0.02 on the NYSE, while PMD trades at $2.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVTA currently has a P/E ratio of -0.00, whereas PMD's P/E ratio is -5.24. In terms of profitability, NVTA's ROE is -2.02%, compared to PMD's ROE of -0.32%. Regarding short-term risk, NVTA is more volatile compared to PMD. This indicates higher risk in terms of short-term price fluctuations for NVTA.Check PMD's competition here
23andMe Holding Co. (NASDAQ: ME)
NVTA vs ME Comparison September 2026
Invitae Corporation (NYSE: NVTA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVTA stands at 5.4M. In comparison, ME has a market cap of 15.3M. Regarding current trading prices, NVTA is priced at $0.02 on the NYSE, while ME trades at $0.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVTA currently has a P/E ratio of -0.00, whereas ME's P/E ratio is -0.03. In terms of profitability, NVTA's ROE is -2.02%, compared to ME's ROE of -42.03%. Regarding short-term risk, NVTA is more volatile compared to ME. This indicates higher risk in terms of short-term price fluctuations for NVTA.Check ME's competition here
Mainz Biomed B.V. (NASDAQ: MYNZ)
NVTA vs MYNZ Comparison September 2026
Invitae Corporation (NYSE: NVTA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVTA stands at 5.4M. In comparison, MYNZ has a market cap of 14.7M. Regarding current trading prices, NVTA is priced at $0.02 on the NYSE, while MYNZ trades at $3.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVTA currently has a P/E ratio of -0.00, whereas MYNZ's P/E ratio is -0.68. In terms of profitability, NVTA's ROE is -2.02%, compared to MYNZ's ROE of -1.80%. Regarding short-term risk, NVTA is more volatile compared to MYNZ. This indicates higher risk in terms of short-term price fluctuations for NVTA.Check MYNZ's competition here
Burning Rock Biotech Limited (NASDAQ: BNR)
NVTA vs BNR Comparison September 2026
Invitae Corporation (NYSE: NVTA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVTA stands at 5.4M. In comparison, BNR has a market cap of 12.2M. Regarding current trading prices, NVTA is priced at $0.02 on the NYSE, while BNR trades at $13.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVTA currently has a P/E ratio of -0.00, whereas BNR's P/E ratio is -13.29. In terms of profitability, NVTA's ROE is -2.02%, compared to BNR's ROE of -0.13%. Regarding short-term risk, NVTA is more volatile compared to BNR. This indicates higher risk in terms of short-term price fluctuations for NVTA.Check BNR's competition here
Advanced Biomed Inc. Common Stock (NASDAQ: ADVB)
NVTA vs ADVB Comparison September 2026
Invitae Corporation (NYSE: NVTA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVTA stands at 5.4M. In comparison, ADVB has a market cap of 11.2M. Regarding current trading prices, NVTA is priced at $0.02 on the NYSE, while ADVB trades at $8.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVTA currently has a P/E ratio of -0.00, whereas ADVB's P/E ratio is -73.45. In terms of profitability, NVTA's ROE is -2.02%, compared to ADVB's ROE of -0.21%. Regarding short-term risk, NVTA is more volatile compared to ADVB. This indicates higher risk in terms of short-term price fluctuations for NVTA.Check ADVB's competition here
Check-Cap Ltd. (NASDAQ: CHEK)
NVTA vs CHEK Comparison September 2026
Invitae Corporation (NYSE: NVTA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVTA stands at 5.4M. In comparison, CHEK has a market cap of 10.9M. Regarding current trading prices, NVTA is priced at $0.02 on the NYSE, while CHEK trades at $1.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVTA currently has a P/E ratio of -0.00, whereas CHEK's P/E ratio is -0.43. In terms of profitability, NVTA's ROE is -2.02%, compared to CHEK's ROE of -2.26%. Regarding short-term risk, NVTA is more volatile compared to CHEK. This indicates higher risk in terms of short-term price fluctuations for NVTA.Check CHEK's competition here
Centogene N.V. (NASDAQ: CNTG)
NVTA vs CNTG Comparison September 2026
Invitae Corporation (NYSE: NVTA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVTA stands at 5.4M. In comparison, CNTG has a market cap of 9.4M. Regarding current trading prices, NVTA is priced at $0.02 on the NYSE, while CNTG trades at $0.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVTA currently has a P/E ratio of -0.00, whereas CNTG's P/E ratio is -0.23. In terms of profitability, NVTA's ROE is -2.02%, compared to CNTG's ROE of +3.98%. Regarding short-term risk, NVTA is more volatile compared to CNTG. This indicates higher risk in terms of short-term price fluctuations for NVTA.Check CNTG's competition here
ENDRA Life Sciences Inc. (NASDAQ: NDRA)
NVTA vs NDRA Comparison September 2026
Invitae Corporation (NYSE: NVTA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVTA stands at 5.4M. In comparison, NDRA has a market cap of 7.3M. Regarding current trading prices, NVTA is priced at $0.02 on the NYSE, while NDRA trades at $5.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVTA currently has a P/E ratio of -0.00, whereas NDRA's P/E ratio is -0.73. In terms of profitability, NVTA's ROE is -2.02%, compared to NDRA's ROE of -2.25%. Regarding short-term risk, NVTA is more volatile compared to NDRA. This indicates higher risk in terms of short-term price fluctuations for NVTA.Check NDRA's competition here
Applied DNA Sciences, Inc. (NASDAQ: APDN)
NVTA vs APDN Comparison September 2026
Invitae Corporation (NYSE: NVTA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVTA stands at 5.4M. In comparison, APDN has a market cap of 7.3M. Regarding current trading prices, NVTA is priced at $0.02 on the NYSE, while APDN trades at $5.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVTA currently has a P/E ratio of -0.00, whereas APDN's P/E ratio is -0.10. In terms of profitability, NVTA's ROE is -2.02%, compared to APDN's ROE of -7.23%. Regarding short-term risk, NVTA is more volatile compared to APDN. This indicates higher risk in terms of short-term price fluctuations for NVTA.Check APDN's competition here
LumiraDx Limited (NASDAQ: LMDX)
NVTA vs LMDX Comparison September 2026
Invitae Corporation (NYSE: NVTA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVTA stands at 5.4M. In comparison, LMDX has a market cap of 5.1M. Regarding current trading prices, NVTA is priced at $0.02 on the NYSE, while LMDX trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVTA currently has a P/E ratio of -0.00, whereas LMDX's P/E ratio is -0.01. In terms of profitability, NVTA's ROE is -2.02%, compared to LMDX's ROE of -15.58%. Regarding short-term risk, NVTA is less volatile compared to LMDX. This indicates lower risk in terms of short-term price fluctuations for NVTA.Check LMDX's competition here
LumiraDx Limited (NASDAQ: LMDXW)
NVTA vs LMDXW Comparison September 2026
Invitae Corporation (NYSE: NVTA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVTA stands at 5.4M. In comparison, LMDXW has a market cap of 5.1M. Regarding current trading prices, NVTA is priced at $0.02 on the NYSE, while LMDXW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVTA currently has a P/E ratio of -0.00, whereas LMDXW's P/E ratio is -0.00. In terms of profitability, NVTA's ROE is -2.02%, compared to LMDXW's ROE of -15.58%. Regarding short-term risk, NVTA is more volatile compared to LMDXW. This indicates higher risk in terms of short-term price fluctuations for NVTA.Check LMDXW's competition here
bioAffinity Technologies, Inc. (NASDAQ: BIAFW)
NVTA vs BIAFW Comparison September 2026
Invitae Corporation (NYSE: NVTA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVTA stands at 5.4M. In comparison, BIAFW has a market cap of 4.6M. Regarding current trading prices, NVTA is priced at $0.02 on the NYSE, while BIAFW trades at $0.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVTA currently has a P/E ratio of -0.00, whereas BIAFW's P/E ratio is 0.49. In terms of profitability, NVTA's ROE is -2.02%, compared to BIAFW's ROE of -2.57%. Regarding short-term risk, NVTA is more volatile compared to BIAFW. This indicates higher risk in terms of short-term price fluctuations for NVTA.Check BIAFW's competition here
DermTech, Inc. (NASDAQ: DMTK)
NVTA vs DMTK Comparison September 2026
Invitae Corporation (NYSE: NVTA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVTA stands at 5.4M. In comparison, DMTK has a market cap of 3.3M. Regarding current trading prices, NVTA is priced at $0.02 on the NYSE, while DMTK trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVTA currently has a P/E ratio of -0.00, whereas DMTK's P/E ratio is -0.04. In terms of profitability, NVTA's ROE is -2.02%, compared to DMTK's ROE of -1.06%. Regarding short-term risk, NVTA is more volatile compared to DMTK. This indicates higher risk in terms of short-term price fluctuations for NVTA.Check DMTK's competition here
Inotiv, Inc. (NASDAQ: NOTV)
NVTA vs NOTV Comparison September 2026
Invitae Corporation (NYSE: NVTA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVTA stands at 5.4M. In comparison, NOTV has a market cap of 2.8M. Regarding current trading prices, NVTA is priced at $0.02 on the NYSE, while NOTV trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVTA currently has a P/E ratio of -0.00, whereas NOTV's P/E ratio is -0.03. In terms of profitability, NVTA's ROE is -2.02%, compared to NOTV's ROE of -0.75%. Regarding short-term risk, NVTA is more volatile compared to NOTV. This indicates higher risk in terms of short-term price fluctuations for NVTA.Check NOTV's competition here
bioAffinity Technologies, Inc. (NASDAQ: BIAF)
NVTA vs BIAF Comparison September 2026
Invitae Corporation (NYSE: NVTA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVTA stands at 5.4M. In comparison, BIAF has a market cap of 2.6M. Regarding current trading prices, NVTA is priced at $0.02 on the NYSE, while BIAF trades at $6.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVTA currently has a P/E ratio of -0.00, whereas BIAF's P/E ratio is -0.73. In terms of profitability, NVTA's ROE is -2.02%, compared to BIAF's ROE of -2.57%. Regarding short-term risk, NVTA is more volatile compared to BIAF. This indicates higher risk in terms of short-term price fluctuations for NVTA.Check BIAF's competition here
SeqLL Inc. (NASDAQ: SQL)
NVTA vs SQL Comparison September 2026
Invitae Corporation (NYSE: NVTA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVTA stands at 5.4M. In comparison, SQL has a market cap of 2.5M. Regarding current trading prices, NVTA is priced at $0.02 on the NYSE, while SQL trades at $6.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVTA currently has a P/E ratio of -0.00, whereas SQL's P/E ratio is -0.40. In terms of profitability, NVTA's ROE is -2.02%, compared to SQL's ROE of -30.46%. Regarding short-term risk, NVTA is more volatile compared to SQL. This indicates higher risk in terms of short-term price fluctuations for NVTA.Check SQL's competition here
Aspira Women's Health Inc. (NASDAQ: AWH)
NVTA vs AWH Comparison September 2026
Invitae Corporation (NYSE: NVTA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVTA stands at 5.4M. In comparison, AWH has a market cap of 2.5M. Regarding current trading prices, NVTA is priced at $0.02 on the NYSE, while AWH trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVTA currently has a P/E ratio of -0.00, whereas AWH's P/E ratio is -0.09. In terms of profitability, NVTA's ROE is -2.02%, compared to AWH's ROE of +1.62%. Regarding short-term risk, NVTA is more volatile compared to AWH. This indicates higher risk in terms of short-term price fluctuations for NVTA.Check AWH's competition here
HTG Molecular Diagnostics, Inc. (NASDAQ: HTGM)
NVTA vs HTGM Comparison September 2026
Invitae Corporation (NYSE: NVTA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVTA stands at 5.4M. In comparison, HTGM has a market cap of 1.1M. Regarding current trading prices, NVTA is priced at $0.02 on the NYSE, while HTGM trades at $0.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVTA currently has a P/E ratio of -0.00, whereas HTGM's P/E ratio is -0.03. In terms of profitability, NVTA's ROE is -2.02%, compared to HTGM's ROE of -2.73%. Regarding short-term risk, NVTA is more volatile compared to HTGM. This indicates higher risk in terms of short-term price fluctuations for NVTA.Check HTGM's competition here
Biocept, Inc. (NASDAQ: BIOC)
NVTA vs BIOC Comparison September 2026
Invitae Corporation (NYSE: NVTA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVTA stands at 5.4M. In comparison, BIOC has a market cap of 450.8K. Regarding current trading prices, NVTA is priced at $0.02 on the NYSE, while BIOC trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVTA currently has a P/E ratio of -0.00, whereas BIOC's P/E ratio is -0.01. In terms of profitability, NVTA's ROE is -2.02%, compared to BIOC's ROE of -1.38%. Regarding short-term risk, NVTA is more volatile compared to BIOC. This indicates higher risk in terms of short-term price fluctuations for NVTA.Check BIOC's competition here
iSpecimen Inc. (NASDAQ: ISPC)
NVTA vs ISPC Comparison September 2026
Invitae Corporation (NYSE: NVTA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVTA stands at 5.4M. In comparison, ISPC has a market cap of 184.7K. Regarding current trading prices, NVTA is priced at $0.02 on the NYSE, while ISPC trades at $1.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVTA currently has a P/E ratio of -0.00, whereas ISPC's P/E ratio is -0.04. In terms of profitability, NVTA's ROE is -2.02%, compared to ISPC's ROE of -5.24%. Regarding short-term risk, NVTA is more volatile compared to ISPC. This indicates higher risk in terms of short-term price fluctuations for NVTA.Check ISPC's competition here
SeqLL Inc. (NASDAQ: SQLLW)
NVTA vs SQLLW Comparison September 2026
Invitae Corporation (NYSE: NVTA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVTA stands at 5.4M. In comparison, SQLLW has a market cap of 179.6K. Regarding current trading prices, NVTA is priced at $0.02 on the NYSE, while SQLLW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVTA currently has a P/E ratio of -0.00, whereas SQLLW's P/E ratio is -0.00. In terms of profitability, NVTA's ROE is -2.02%, compared to SQLLW's ROE of -30.46%. Regarding short-term risk, NVTA is more volatile compared to SQLLW. This indicates higher risk in terms of short-term price fluctuations for NVTA.Check SQLLW's competition here
GeneDx Holdings Corp. (NASDAQ: WGSWW)
NVTA vs WGSWW Comparison September 2026
Invitae Corporation (NYSE: NVTA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVTA stands at 5.4M. In comparison, WGSWW has a market cap of 5.8K. Regarding current trading prices, NVTA is priced at $0.02 on the NYSE, while WGSWW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVTA currently has a P/E ratio of -0.00, whereas WGSWW's P/E ratio is -0.00. In terms of profitability, NVTA's ROE is -2.02%, compared to WGSWW's ROE of -0.39%. Regarding short-term risk, NVTA is more volatile compared to WGSWW. This indicates higher risk in terms of short-term price fluctuations for NVTA.Check WGSWW's competition here
Ortho Clinical Diagnostics Holdings plc (NASDAQ: OCDX)
NVTA vs OCDX Comparison September 2026
Invitae Corporation (NYSE: NVTA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVTA stands at 5.4M. In comparison, OCDX has a market cap of 0. Regarding current trading prices, NVTA is priced at $0.02 on the NYSE, while OCDX trades at $17.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVTA currently has a P/E ratio of -0.00, whereas OCDX's P/E ratio is -42.28. In terms of profitability, NVTA's ROE is -2.02%, compared to OCDX's ROE of +0.18%. Regarding short-term risk, NVTA is more volatile compared to OCDX. This indicates higher risk in terms of short-term price fluctuations for NVTA.Check OCDX's competition here
BioNano Genomics, Inc. WT EXP 082123 (NASDAQ: BNGOW)
NVTA vs BNGOW Comparison September 2026
Invitae Corporation (NYSE: NVTA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVTA stands at 5.4M. In comparison, BNGOW has a market cap of 0. Regarding current trading prices, NVTA is priced at $0.02 on the NYSE, while BNGOW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVTA currently has a P/E ratio of -0.00, whereas BNGOW's P/E ratio is N/A. In terms of profitability, NVTA's ROE is -2.02%, compared to BNGOW's ROE of -0.79%. Regarding short-term risk, NVTA is less volatile compared to BNGOW. This indicates lower risk in terms of short-term price fluctuations for NVTA.Check BNGOW's competition here
PAREXEL Intl Corp. (NASDAQ: PRXL)
NVTA vs PRXL Comparison September 2026
Invitae Corporation (NYSE: NVTA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVTA stands at 5.4M. In comparison, PRXL has a market cap of 0. Regarding current trading prices, NVTA is priced at $0.02 on the NYSE, while PRXL trades at $88.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVTA currently has a P/E ratio of -0.00, whereas PRXL's P/E ratio is 42.97. In terms of profitability, NVTA's ROE is -2.02%, compared to PRXL's ROE of +0.17%. Regarding short-term risk, NVTA is more volatile compared to PRXL. This indicates higher risk in terms of short-term price fluctuations for NVTA.Check PRXL's competition here
23andMe Holding Co. (NASDAQ: MEUSW)
NVTA vs MEUSW Comparison September 2026
Invitae Corporation (NYSE: NVTA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVTA stands at 5.4M. In comparison, MEUSW has a market cap of 0. Regarding current trading prices, NVTA is priced at $0.02 on the NYSE, while MEUSW trades at $1.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVTA currently has a P/E ratio of -0.00, whereas MEUSW's P/E ratio is N/A. In terms of profitability, NVTA's ROE is -2.02%, compared to MEUSW's ROE of -42.03%. Regarding short-term risk, NVTA is more volatile compared to MEUSW. This indicates higher risk in terms of short-term price fluctuations for NVTA.Check MEUSW's competition here
ENDRA Life Sciences Inc. Warrants (NASDAQ: NDRAW)
NVTA vs NDRAW Comparison September 2026
Invitae Corporation (NYSE: NVTA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVTA stands at 5.4M. In comparison, NDRAW has a market cap of 0. Regarding current trading prices, NVTA is priced at $0.02 on the NYSE, while NDRAW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVTA currently has a P/E ratio of -0.00, whereas NDRAW's P/E ratio is N/A. In terms of profitability, NVTA's ROE is -2.02%, compared to NDRAW's ROE of -2.25%. Regarding short-term risk, NVTA is less volatile compared to NDRAW. This indicates lower risk in terms of short-term price fluctuations for NVTA.Check NDRAW's competition here
Danaher Corporation (NYSE: DHR-PA)
NVTA vs DHR-PA Comparison September 2026
Invitae Corporation (NYSE: NVTA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVTA stands at 5.4M. In comparison, DHR-PA has a market cap of 0. Regarding current trading prices, NVTA is priced at $0.02 on the NYSE, while DHR-PA trades at $1,841.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVTA currently has a P/E ratio of -0.00, whereas DHR-PA's P/E ratio is 233.57. In terms of profitability, NVTA's ROE is -2.02%, compared to DHR-PA's ROE of +0.08%. Regarding short-term risk, NVTA is more volatile compared to DHR-PA. This indicates higher risk in terms of short-term price fluctuations for NVTA.Check DHR-PA's competition here
Check-Cap Ltd (NASDAQ: CHEKZ)
NVTA vs CHEKZ Comparison September 2026
Invitae Corporation (NYSE: NVTA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVTA stands at 5.4M. In comparison, CHEKZ has a market cap of 0. Regarding current trading prices, NVTA is priced at $0.02 on the NYSE, while CHEKZ trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVTA currently has a P/E ratio of -0.00, whereas CHEKZ's P/E ratio is N/A. In terms of profitability, NVTA's ROE is -2.02%, compared to CHEKZ's ROE of +4.17%. Regarding short-term risk, NVTA is more volatile compared to CHEKZ. This indicates higher risk in terms of short-term price fluctuations for NVTA.Check CHEKZ's competition here